日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases.

评估白细胞介素-6及其可溶性受体成分sIL-6R和sgp130作为炎症性肠病炎症标志物的价值

Nikolaus Susanna, Waetzig Georg H, Butzin Sven, Ziolkiewicz Monika, Al-Massad Natalie, Thieme Florian, Lövgren Ulf, Rasmussen Birgitte B, Reinheimer Torsten M, Seegert Dirk, Rosenstiel Philip, Szymczak Silke, Schreiber Stefan

Divergent estrogen receptor-positive and -negative breast cancer trends and etiologic heterogeneity in Denmark

丹麦雌激素受体阳性和阴性乳腺癌的趋势差异及病因异质性

Anderson, William F; Rosenberg, Philip S; Petito, Lucia; Katki, Hormuzd A; Ejlertsen, Bent; Ewertz, Marianne; Rasmussen, Birgitte B; Jensen, Maj-Britt; Kroman, Niels

Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy

Bcl-2 在接受辅助内分泌治疗的两组独立的雌激素受体阳性乳腺癌患者中的预后价值

Larsen, Mathilde S; Bjerre, Karsten; Giobbie-Hurder, Anita; Lænkholm, Anne-Vibeke; Henriksen, Katrine L; Ejlertsen, Bent; Lykkesfeldt, Anne E; Rasmussen, Birgitte B

In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer

原发肿瘤中芳香化酶的表达与雌激素受体的表达相关,但不能预测晚期乳腺癌对内分泌治疗的反应。

Lykkesfeldt, Anne E; Henriksen, Katrine L; Rasmussen, Birgitte B; Sasano, Hironobu; Evans, Dean B; Møller, Susanne; Ejlertsen, Bent; Mouridsen, Henning T

Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays

乳腺癌内分泌治疗潜在预测标志物的半定量评分:全切片与组织微阵列的比较

Henriksen, Katrine L; Rasmussen, Birgitte B; Lykkesfeldt, Anne E; Møller, Susann; Ejlertsen, Bent; Mouridsen, Henning T